Kary Eldred
CIK: 0001543425
Kary Eldred's purchase track record
How the stock did after each of Kary Eldred's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
8
of 8 since February 21, 2023
Stock higher 6 months later
75%
3 months: 63%
Median 6-month return
+7.4%
3 months: +17.9%
Beat the S&P 500
63%
median +1.4% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/6/2026 | GALT | $810 | -25.0% | +23.2% | +11.9% |
| 12/23/2025 | GALT | $5K | -29.1% | -21.8% | +6.6% |
| 7/21/2025 | GALT | $3K | +85.8% | +9.1% | +7.8% |
| 12/24/2024 | GALT | $11K | +110.7% | +188.1% | +0.9% |
| 10/23/2024 | GALT | $1K | -53.1% | -48.1% | -7.3% |
| 1/16/2024 | GALT | $2K | +86.8% | +38.5% | +18.9% |
| 7/19/2023 | GALT | $3K | +23.4% | +5.3% | +3.8% |
| 2/21/2023 | GALT | $2K | +12.5% | +5.6% | +9.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| GALT | ▲ Buy | Open Market | 300 | $810 | 2/6/2026 | View on chart |
| GALT | ▲ Buy | Open Market | 700 | $3K | 12/23/2025 | View on chart |
| GALT | ▲ Buy | Open Market | 700 | $3K | 12/23/2025 | View on chart |
| GALT | ▲ Buy | Open Market | 1,000 | $3K | 7/21/2025 | View on chart |
| GALT | ▲ Buy | Open Market | 13,469 | $11K | 12/24/2024 | View on chart |
| GALT | ▲ Buy | Open Market | 500 | $1K | 10/23/2024 | View on chart |
| GALT | ▲ Buy | Open Market | 500 | $893 | 1/16/2024 | View on chart |
| GALT | ▲ Buy | Open Market | 400 | $956 | 1/16/2024 | View on chart |
| GALT | ▲ Buy | Open Market | 1,598 | $3K | 7/19/2023 | View on chart |
| GALT | ▲ Buy | Open Market | 1,000 | $2K | 2/21/2023 | View on chart |
| GALT | ▲ Buy | Open Market | 1,300 | $1K | 1/25/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Galectin Clears Balance Sheet with $105M Debt Conversion
Galectin Therapeutics announced that a $105 million debt conversion has removed its outstanding debt, improving its balance sheet. The company still needs to secure a Phase 3 partnership to move its lead product forward. The move may reduce financial risk but the next milestone remains critical for the company's progress.
Galectin Clears Balance Sheet with $105M Debt Conversion. Galectin Therapeutics announced that a $105 million debt conversion has removed its outstanding debt, improving its balance sheet. The company still needs to secure a Phase 3 partnership to move its lead product forward. The move may reduce financial risk but the next milestone remains critical for the company's progress.